Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Nonlinear Inverse Association Seen for Step Count, Peak Cadence With MACE
THURSDAY, Aug. 7, 2025 -- There are nonlinear, inverse associations for step count and peak cadence with the risk for major adverse cardiovascular events...
55 Percent of Calories Come From Ultraprocessed Foods in the United States
THURSDAY, Aug. 7, 2025 -- The mean percentage of total calories consumed from ultraprocessed foods was 55.0 percent among those aged 1 year and older during...
FDA Approves SetPoint Neuroimmune Modulation Device for Rheumatoid Arthritis
THURSDAY, Aug. 7, 2025 -- The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults...
History of Pregnancy Complications Associated With Increased Ischemic Stroke Risk
THURSDAY, Aug. 7, 2025 -- Women with a history of pregnancy complications may have an increased risk for ischemic stroke at a young age (younger than 50...
Higher Intake of Total Potatoes Linked to Type 2 Diabetes Risk
THURSDAY, Aug. 7, 2025 -- A higher intake of total potatoes, especially French fries, is associated with an increased risk for type 2 diabetes (T2D), according...
Oseltamivir for Flu Tied to Reduced Risk for Serious Neuropsychiatric Events in Children
THURSDAY, Aug. 7, 2025 -- Oseltamivir treatment during influenza episodes is associated with a reduced risk for serious neuropsychiatric events among children...
California Wildfires May Have Caused Hundreds More Deaths
THURSDAY, Aug. 7, 2025 — Wildfires that tore through Los Angeles early this year may have caused hundreds more deaths than official reports show, new...
FDA Warns About Safety Issues With Boston Scientific Heart Devices
THURSDAY, Aug. 7, 2025 — U.S. health officials are warning patients and physicians about safety issues associated with two Boston Scientific heart...
RFK Jr. Cancels $500M in mRNA Vaccine Research Projects
THURSDAY, Aug. 7, 2025 — U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has canceled nearly $500 million in grants...
Tamiflu Safe For Children, Study Concludes
THURSDAY, Aug. 7, 2025 — Researchers have debunked long-standing concerns that Tamiflu can cause neurological and psychiatric problems when given to...
FDA Grants Accelerated Approval to Modeyso (dordaviprone) for the Treatment of Recurrent H3 K27M-Mutant Diffuse Midline Glioma
DUBLIN, Aug. 6, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted...
FDA Approves Expanded Indication for Ajovy (fremanezumab-vfrm), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE...
FDA Approves Vostally (ramipril) Oral Solution for the Treatment of Hypertension in Adults
Greenville, SC – July 31, 2025 – Rosemont Pharmaceuticals, Inc. announced that on July 23, 2025, the U.S. Food and Drug Administration (FDA) has...
FDA Approves Vizz (aceclidine ophthalmic solution) for the Treatment of Presbyopia
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), today announced the US...
FDA Approves Alhemo as Once-Daily Prophylactic Treatment to Prevent or Reduce the Frequency of Bleeding Episodes for Adults and Children 12 Years of Age and Older with Hemophilia A or B (HA/HB) Without Inhibitors
PLAINSBORO, N.J., July 31, 2025 /PRNewswire/ -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) approved Alhemo (concizumab-mtci)...
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
SECAUCUS, N.J., July 24, 2025 /PRNewswire/ -- Pierre Fabre Pharmaceuticals Inc. (PFP) announces the acceptance by U.S. Food and Drug Administration (FDA) of...
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of...
Johnson & Johnson Seeks First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
SPRING HOUSE, Pa. (July 21, 2025) – Johnson & Johnson (NYSE: JNJ) today announced the submission of a New Drug Application (NDA) to the U.S. Food...
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 17, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug...
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 14, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery...
Boehringer and Click Therapeutics’ Investigational Prescription Digital Therapeutic CT-155 Meets Primary Endpoint in CONVOKE Study for Negative Symptoms in Schizophrenia
Ingelheim, Germany / Ridgefield, Connecticut / New York, New York, Thu, August 7, 2025 -- Boehringer Ingelheim and Click Therapeutics today announced that the...
Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of Up To an Average of 27.3 lbs in First of Two Pivotal Phase 3 Trials in Adults with Obesity
INDIANAPOLIS, Aug. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial...
U.S. FDA Granted Fast Track Designation to Dizal’s Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
August 6, 2025 – Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological...
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
BOSTON--(BUSINESS WIRE)--Aug. 4, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2...
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.